Discovery of microsomal triglyceride transfer protein (MTP) inhibitors with potential for decreased active metabolite load compared to dirlotapide

  • Bioorg Med Chem Lett. 2011 Jul 15;21(14):4150-4. doi: 10.1016/j.bmcl.2011.05.099.
Ralph P Robinson  1 ,  Jeremy A Bartlett ,  Peter Bertinato ,  Andrew J Bessire ,  Judith Cosgrove ,  Patrick M Foley ,  Tara B Manion ,  Martha L Minich ,  Brenda Ramos ,  Matthew R Reese ,  Theodore J Schmahai ,  Andrew G Swick ,  David A Tess ,  Alfin Vaz ,  Angela Wolford
Affiliations
  • 1. Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc., Groton, CT 06340, USA. [email protected]
PMID: 21684740 DOI: 10.1016/j.bmcl.2011.05.099
Abstract

Analogues related to dirlotapide (1), a gut-selective inhibitor of microsomal triglyceride transfer protein (MTP) were prepared with the goal of further reducing the potential for unwanted liver MTP inhibition and associated side-effects. Compounds were designed to decrease active metabolite load: reducing MTP activity of likely human metabolites and increasing metabolite clearance to reduce exposure. Introduction of 4'-alkyl and 4'-alkoxy substituents afforded compounds exhibiting improved therapeutic index in rats with respect to liver triglyceride accumulation and enzyme elevation. Likely human metabolites of select compounds were prepared and characterized for their potential to inhibit MTP in vivo. Based on preclinical efficacy and safety data and its potential for producing short-lived, weakly active metabolites, compound 13 (PF-02575799) advanced into phase 1 clinical studies.

Products